Physician profile

Jon B Olson

Pain Medicine · Edmonds, WA

NPI 1487703922

$1,978.60

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Supernus Pharmaceuticals, INC. $183.04 2019-2020
Collegium Pharmaceutical, INC. $179.57 2019-2020
Zyla Life Sciences, INC. $163.99 2020
Sentynl Therapeutics, INC. $139.34 2019
Teva Pharmaceuticals USA, INC. $139.02 2019-2020
Horizon Therapeutics Plc $136.63 2019
Pfizer INC. $127.98 2019-2020
Scilex Pharmaceuticals INC. $122.61 2019
Assertio Therapeutics, INC. $99.28 2019-2020
Indivior INC. $94.65 2019
Lilly USA, LLC $87.35 2019-2020
Amgen INC. $74.95 2019-2020
Vertical Pharmaceuticals, LLC $60.56 2019
Daiichi Sankyo INC. $57.64 2019
Allergan, INC. $57.28 2020
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $55.33 2019
Kaleo, INC. $46.52 2019
Arbor Pharmaceuticals, INC. $33.82 2019-2020
Stimwave Technologies Incorporated $24.83 2019
Biodelivery Sciences International, INC. $23.91 2019
Grt US Holding, INC. $22.86 2019
Gilead Sciences, INC. $21.09 2019
Orexo US, INC. $13.81 2020
Neuronetics, INC. $12.54 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jon B Olson

$1,978.60

in general payments reported 2019-2025

Years
2019-2020
Top company
Supernus Pharmaceuticals, INC.

https://glasscript.com/doctor/294623/jon-b-olson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.